A new era for radiolabeled antibodies in cancer?
Curr Opin Immunol
; 11(5): 563-9, 1999 Oct.
Article
em En
| MEDLINE
| ID: mdl-10508716
ABSTRACT
Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Radioimunoterapia
/
Compostos Radiofarmacêuticos
/
Anticorpos Antineoplásicos
/
Neoplasias
Limite:
Female
/
Humans
Idioma:
En
Revista:
Curr Opin Immunol
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Estados Unidos